Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.78 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | PDE4A | P27815 | 2/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123678 | 1.00 | PDE10A (0.78) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| Mardepodect SCHEMBL29496270 | 0.88 | PDE10A (1.00) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL30123358 | 0.88 | PDE10A (1.00) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| Mardepodect SCHEMBL1414700 | 0.88 | PDE10A (1.00) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL3271928 | 0.88 | PDE10A (1.00) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL3273949 | 0.87 | PDE10A (0.75) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL30123269 | 0.87 | PDE10A (0.75) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| Mardepodect SCHEMBL29435412 | 0.87 | PDE10A (0.98) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| Mardepodect SCHEMBL30357427 | 0.87 | PDE10A (0.98) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL30123420 | 0.86 | PDE10A (0.79) | PDE10ALGALS3PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102491969-A | Heteroaromatic quinoline compounds | PFIZER PROD INC | 2012-06-13 | — | — | CN | claimed |
| EP-1841757-B1 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PROD INC (US) | 2010-06-30 | — | — | EP | claimed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | claimed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | claimed |
| CN-101098866-A | Heteroaromatic quinoline compounds and their use as pde10 inhibitors | PFIZER (US) | 2008-01-02 | — | — | CN | claimed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | claimed |
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-10039764-B2 | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression | UNIVERSITY OF SOUTH ALABAMA (US) | 2018-08-07 | — | — | US | disclosed |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | UNIVERSITY OF SOUTH ALABAMA (US) | 2016-05-26 | — | — | US | disclosed |
| CN-102491969-B | Heteroaromatic quinoline compounds and the purposes as PDE10 inhibitor thereof | PFIZER PRODUCTS INC. (US) | 2015-08-19 | — | — | CN | disclosed |
| WO-2015006689-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | UNIVERSITY OF SOUTH ALABAMA (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2675456-A1 | METHODS FOR TREATING DISEASES OF THE RETINA | Allergan, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012112918-A1 | METHODS FOR TREATING DISEASES OF THE RETINA | ALLERGAN, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
| EP-1841757-B1 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PROD INC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | disclosed |
| CN-101098866-A | Heteroaromatic quinoline compounds and their use as pde10 inhibitors | PFIZER (US) | 2008-01-02 | — | — | CN | disclosed |
| EP-1841757-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | disclosed |
| WO-2006072828-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039764-B2 | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression | PDE4A, PDE7B, PDE2A | PDE10A 12/4885LGALS3 2425/4885PDE4D 13/4885 |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PDE12, PDE7A, PDE4A | PDE10A 8/4885LGALS3 4568/4885PDE4D 17/4885 |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PDE12, PDE7A, PDE4A | PDE10A 8/4885LGALS3 4568/4885PDE4D 17/4885 |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | PDE4A, PDE7B, PDE2A | PDE10A 12/4885LGALS3 2425/4885PDE4D 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.